Long Term Outcomes after Pediatric Liver Transplantation.
10.5223/pghn.2013.16.4.207
- Author:
Nada A YAZIGI
1
Author Information
1. MedStar Georgetown Transplant Institute, Georgetown University Hospital, Washington DC, USA. nada.a.yazigi@gunet.georgetown.edu
- Publication Type:Review
- Keywords:
Children;
Liver;
Transplants;
Patients outcome
- MeSH:
Child;
Chronic Disease;
Coinfection;
Efficiency;
Executive Function;
Graft Survival;
Hepatitis, Autoimmune;
Humans;
Immunosuppression;
Kidney;
Liver Diseases;
Liver Transplantation*;
Liver*;
Quality of Life;
Transplants
- From:Pediatric Gastroenterology, Hepatology & Nutrition
2013;16(4):207-218
- CountryRepublic of Korea
- Language:English
-
Abstract:
Long term outcomes after liver transplantation are major determinants of quality of life and of the value of this heroic treatment. As short term outcomes are excellent, our community is turning to take a harder look at long term outcomes. The purpose of this paper is to review these outcomes, and highlight proposed treatments, as well as pressing topics needing to be studied. A systemic review of the English literature was carried in PubMed, covering all papers addressing long term outcomes in pediatric liver transplant from 2000-2013. Late outcomes after pediatric liver transplant affect the liver graft in the form of chronic liver dysfunction. The causes include rejection particularly humoral rejection, but also de novo autoimmune hepatitis, and recurrent disease. The metabolic syndrome is a major factor in long term cardiovascular complication risk. Secondary infections, kidney dysfunction and malignancy remain a reality of those patients. There is growing evidence of late cognitive and executive function delays affecting daily life productivity as well as likely adherence. Finally, despite a good health status, quality of life measures are comparable to those of children with chronic diseases. Long term outcomes are the new frontier in pediatric liver transplantation. Much is needed to improve graft survival, but also to avoid systemic morbidities from long term immunosuppression. Quality of life is a new inclusive measure that will require interventions and innovative approaches respectful not only on the patients but also of their social circle.
